drugset / Trial / NCT02382666

A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers

NCT02382666

Phase 1 Completed 100 enrolled Tesaro, Inc.
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to assess the safety and tolerability of single increasing doses of intravenously administered rolapitant in healthy male and female subjects.

Timeline

Start
2015-01
Primary completion
2015-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Rolapitant Small molecule Intravenous